Critics Unmoved by Economic Report; Still Say No More Billions for California's Stem Cell Agency
By David Jensen,
California Stem Cell Report
| 10. 10. 2019
This week's relatively rosy report on the economic impact of California's $3 billion stem cell research program has not convinced longtime critics to change their positions and support giving it an additional $5 billion.
In the eyes of some opponents, the stem cell agency is still a boondoggle, a waste of money and an inappropriate use of state bonds, the borrowed money that is the only significant source of cash for the program. Other critics recommended moving the program to the University of California and restricting it to "breakthrough medicine."
The agency, known formally as the California Institute for Regenerative Medicine (CIRM), expects to run out of money for new awards this month. It is hoping that voters will see value in its efforts and approve -- in November 2020 -- a $5.5 billion ballot initiative that would refinance the agency.
The 2004 initiative that created CIRM was handily approved by 59 percent of the voters following a campaign that created expectations that nearly miraculous therapies were right around the corner. The agency has yet to back a treatment that...
Related Articles
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...
By Philip Ball, Quanta Magazine | 06.18.2026
Since its molecular structure was deduced in the 1950s, DNA has been hailed by many biologists as the secret of life. They’ve read and studied the information stored in the DNA found in the cells of living organisms, known as...
By Arche Noah, GMWatch | 06.17.2026
The European Parliament has voted for a wide-reaching deregulation of New Genomic Techniques (NGTs). There was no majority for amendments stopping patents on conventionally classically bred plants or NGT plants. “Today’s vote is a missed opportunity to protect Europe’s farmers...